Lilly's EloraTZP (eloralintide + tirzepatide) outperforms tirzepatide 15 mg in Phase 2b obesity and T2D trial

Key highlights
  • EloraTZP (eloralintide + tirzepatide) produced up to 23.3% mean weight loss (54.1 lbs) vs 14.8% (34.4 lbs) with tirzepatide 15 mg.
  • A1C fell up to 2.9% with EloraTZP compared with 2.4% with tirzepatide 15 mg.
  • Phase 2b was a 48‑week, double‑blind study of 367 adults with overweight/obesity and type 2 diabetes, baseline weight 232.4 lbs and A1C 8.1%.
  • Gastrointestinal adverse events were more frequent with the combination; discontinuation rates with EloraTZP ranged 10.8%–27.0%; tirzepatide 2.9%; placebo 16.7%.

Study design

The Phase 2b trial randomized 367 adults with overweight or obesity and type 2 diabetes in the U.S. and Argentina to placebo, eloralintide, tirzepatide or combinations (EloraTZP) for 48 weeks. The primary endpoint was percent change in body weight from an average baseline of 232.4 lbs; a key secondary endpoint was change in A1C from an average baseline of 8.1%.

Efficacy results

All EloraTZP dose combinations met primary and secondary endpoints. The highest-dose combination (eloralintide 9 mg + tirzepatide 15 mg) produced a mean 23.3% weight loss (54.1 lbs) and a 2.9% A1C reduction at 48 weeks. By comparison, tirzepatide 15 mg produced a mean 14.8% weight loss (34.4 lbs) and a 2.4% A1C reduction. Eloralintide alone reduced weight by up to 12.3% (28.6 lbs) and A1C by up to 1.4% versus placebo (−3.0% weight, −0.3% A1C).

Safety and tolerability

The most common adverse events were gastrointestinal and generally mild to moderate, occurring primarily during dose escalation and more frequently in combination arms than with either agent alone. Treatment discontinuation due to adverse events ranged from 10.8% to 27.0% for EloraTZP arms, 0%–10.8% for eloralintide arms, 2.9% for tirzepatide, and 16.7% for placebo.

Next steps

Results were presented at EASD. Lilly plans to initiate Phase 3 studies of an EloraTZP co‑formulation using an optimized escalation schedule by the end of 2026 (Q4 2026).

Source: Lilly

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

29 September 2026
Lilly retatrutide shows large weight loss and A1C reductions in TRIUMPH-2

Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.

23 July 2026
Lilly's retatrutide shows large weight and A1C reductions in Phase 3 TRIUMPH‑2 and TRIUMPH‑3

First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.

31 August 2026
Eli Lilly: Taltz plus Zepbound sustain improved psoriatic and metabolic outcomes at 52 weeks

Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.

28 August 2026
Eli Lilly’s Mounjaro approved by FDA to reduce cardiovascular risk in adults with type 2 diabetes

First GIP+GLP‑1 agonist authorised to lower major adverse cardiovascular events in high‑risk adults with type 2 diabetes; SURPASS‑CVOT enrolled >13,000 with ~4‑year median follow‑up.

21 May 2026
Lilly’s retatrutide achieves up to 30% weight loss in Phase 3 TRIUMPH-1

Phase 3 TRIUMPH-1: three doses met endpoints at 80 weeks with dose-related, substantial weight loss. 104-week extension in BMI≥35 showed further loss; cardiometabolic markers improved; GI AEs common.